TRDA
Entrada Therapeutics, Inc.Healthcare · $239M market cap
Verdict
We can't put a fair value on TRDA right now. Its earnings are too small compared with its share price for an earnings-based value to mean anything.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow TRDA
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 1, 2026: no open-market purchases, 12 sales worth $5.0M and 4 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
MPM BioVentures 2014, L.P.
Owns 10%+ · 2026-09-09
Sold
$206K
MPM BIOVENTURES 2018, L.P.
Owns 10%+ · 2026-09-09
Sold
$206K
MPM BioVentures 2014, L.P.
Owns 10%+ · 2026-09-08
Sold
$1.4M
MPM BIOVENTURES 2018, L.P.
Owns 10%+ · 2026-09-08
Sold
$1.4M
MPM BioVentures 2014, L.P.
Owns 10%+ · 2026-09-04
Sold
$274K
Show all 12 salesShow fewer
MPM BIOVENTURES 2018, L.P.
Owns 10%+ · 2026-09-04
Sold
$274K
MPM BioVentures 2014, L.P.
Owns 10%+ · 2026-09-03
Sold
$231K
MPM BIOVENTURES 2018, L.P.
Owns 10%+ · 2026-09-03
Sold
$231K
MPM BioVentures 2014, L.P.
Owns 10%+ · 2026-09-02
Sold
$181K
MPM BIOVENTURES 2018, L.P.
Owns 10%+ · 2026-09-02
Sold
$181K
MPM BioVentures 2014, L.P.
Owns 10%+ · 2026-09-01
Sold
$205K
MPM BIOVENTURES 2018, L.P.
Owns 10%+ · 2026-09-01
Sold
$205K
Other filings
About Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works